HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...
Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...
ACCP Position Statement: "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor Agonists"
Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...
Basic science researchers at the Johns Hopkins University School of Medicine are advancing heart health research by finding ...
HealthDay on MSN11d
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid CancerGlucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
Viking Therapeutics (NASDAQ: VKTX) shares exploded higher after the clinical-stage drugmaker announced successful results ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback